Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-324219
Filing Date
2026-07-29
Accepted
2026-07-29 17:15:35
Documents
59
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q vktx-20260630.htm   iXBRL 10-Q 2540742
2 EX-10.1 vktx-ex10_1.htm EX-10.1 331287
3 EX-10.2 vktx-ex10_2.htm EX-10.2 114655
4 EX-10.3 vktx-ex10_3.htm EX-10.3 179726
5 EX-31.1 vktx-ex31_1.htm EX-31.1 17964
6 EX-31.2 vktx-ex31_2.htm EX-31.2 17939
7 EX-32.1 vktx-ex32_1.htm EX-32.1 13688
  Complete submission text file 0001193125-26-324219.txt   10074813

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20260630.xsd EX-101.SCH 1066918
62 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20260630_htm.xml XML 1716234
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 500 SAN DIEGO CA
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 500 SAN DIEGO CA 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37355 | Film No.: 261218930
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)